EN DE

Balchem Corporation (BCPC) Fair Value & Analysis

Basic Materials · US · Market cap $5.2B

BC Balchem Corporation logo Balchem Corporation BCPC · US
Price$179.43
Fair Value$81.93
Upside-54.3%
Quality70/100
Watch Balchem Corporation for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Solidly profitable · 15.0% net margin
Low debt · generates free cash flow
0.59% dividend yield
Mixed vs. peers (6/15)
Moderate moat 63/100
Evidence: High Range $61.45 – $102.41 Share as image

Fair value as of: Jul 14, 2026

From 26 valuation models · updated 26 days ago

Share price +8.1% over the past month.

A solid business, but screening 54% overvalued on our models.

What matters now

  • A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case ($102.41). The favourable scenario is already priced in.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$183.26 $110.77 Fair Value $81.93 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 14, 2026.

How to read this chart

60‑month range $110.77 – $183.26 · fair‑value band $61.45 – $102.41 · the $179.43 price screens above the $81.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 14, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Balchem Corporation (BCPC) currently trades at $179.43, while our model-based Fair Value estimate is $81.93, implying the stock looks roughly 54.3% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Balchem Corporation generated revenue of $1.1B at a net margin of 15.0%. Revenue grew 8.1% year over year. It earns a return on equity of 12.7%. Net debt stands at $117M. Fundamentals as of Jul 14, 2026

Our scenario range runs from $61.45 (bear case) to $102.41 (bull case); at $179.43, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 30% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -54%, BCPC screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF $73.17 $141.86 $267.46 80
Residual Income $35.92 $42.72 $92.34 76
Rev-Margin DCF $45.63 $84.98 $143.20 74
All 26 models by family
DCF Models
FCF DCF $76.89 $129.12 $273.27 38
Owner Earnings $69.52 $156.74 $332.49 31
5Y Revenue Exit $45.63 $80.26 $145.30 39
5Y EBITDA Exit $63.01 $118.04 $216.23 41
5Y P/E Exit $62.89 $127.28 $208.95 38
10Y Revenue Exit $53.64 $98.98 $151.01 36
10Y EBITDA Exit $66.91 $130.89 $244.27 37
10Y P/E Exit $66.82 $130.66 $237.45 35
Earnings-Based
Graham-Dodd $32.77 $227.04 $318.52 54
Lynch FV $66.93 $95.62 $124.30 50
PEG = 1.0 $66.93 $95.62 $124.30 46
EPV $46.49 $54.27 $60.98 59
Dividend Discount
Gordon GGM $7.73 $15.41 $23.33 70
DDM Multi-Stage $7.73 $13.32 $16.26 61
Multiples
P/E Multiple $61.45 $81.93 $102.41 63
P/S Multiple $36.32 $48.42 $60.53 58
P/B Multiple $61.45 $81.93 $102.41 55
EV/EBIT $68.57 $92.35 $116.13 53
EV/EBITDA $58.85 $79.39 $99.93 54
EV/Revenue $31.11 $45.64 $60.16 43
Asset-Based
NCAV (Graham) $19.57 $26.22 $39.14 50
Growth DCF
Growth DCF $73.17 $141.86 $267.46 80
Rev-Margin DCF $45.63 $84.98 $143.20 74
Economic Profit
Residual Income $35.92 $42.72 $92.34 76
ROIC Compounder $52.28 $75.84 $94.41 72
Growth Earnings
Growth-Adj P/E $84.25 $120.36 $156.46 68

Widest divergence: DCF Models ($127.28) versus Dividend Discount ($13.32). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) $1.1B
Revenue growth (YoY) +8.1%
Net margin 15.0%
Return on equity 12.7%
Free cash flow $173M FY2025
P/E ratio 33.2
More key figures
Operating margin 20.9%
EPS (TTM) $4.88
Dividend yield 0.6%
EPS growth (YoY) +10.6%
Net debt $117M FY2025

Figures from reported company fundamentals · as of Jul 14, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 70/100

Of which business quality 68 · Market factors (momentum, volatility) 65

Profitability 51
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 76
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 51
Price trend over the last 3–12 months (market factor)
52W Momentum 71
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.

Full company description

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Balchem Corporation reported revenue of $1.0B in FY2025 versus $799M in FY2021, a compound +6.7%/yr. Reported net income was $155M in FY2025, compounding +12.7%/yr from FY2021.

Growth Quality 86/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$1.0B
Latest YoY
+8.8%
Avg. growth/yr (3Y)
+3.2%
Avg. growth/yr (5Y)
+8.1%
Avg. growth/yr (40Y)
+14.2%
Revenue +6.7%/yr
FY21 $799M
FY22 $942M
FY23 $922M
FY24 $954M
FY25 $1.0B
Net income +12.7%/yr
FY21 $96.1M
FY22 $105M
FY23 $109M
FY24 $128M
FY25 $155M

BCPC screens 54% overvalued. Compare with Linde plc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Balchem Corporation Fair Value". https://www.fairvalue-calculator.com/stock/BCPC

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Specialty Chemicals · 676 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 70 · Top 25%
Fair Value upside −54% · Below median
Return on equity (TTM) 13% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 15% · Top 25%
Operating margin (TTM) 21% · Top 25%
Revenue growth 8% · Above median
Dividend yield (TTM) 0.6% · Below median
Debt / equity 0.13× · Higher than median

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 33.2× · Pricier than median
P/B 4.14× · Pricier than 75% of peers
P/S (TTM) 4.93× · Pricier than 75% of peers
P/FCF 30.1× · Pricier than 75% of peers
EV/EBITDA 20.3× · Pricier than 75% of peers
PEG 3.72× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 41 · sector 19
PAST 51 · sector 23
HEALTH 94 · sector 95
DIVIDEND 12 · sector 25

VALUE 0: the price sits above our fair-value range.

Insider activity: 45/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $489.98 $222.03 -55%
Nan Ya Plastics Corporation 1303 181.50 TWD 255.83 TWD +41%
Wanhua Chemical Group 600309 ¥70.04 ¥68.03 -3%
Novozymes A/S NSISB kr 428.20 kr 179.66 -58%
Asian Paints Limited ASIANPAINT ₹2,689 ₹668.81 -75%
Solar Industries India Limited SOLARINDS ₹18,236 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,560 ₹351.84 -77%
PT Chandra Asri Pacific Tbk TPIA 1,805 IDR 2,888 IDR +60%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%
Berger Paints India Limited BERGEPAINT ₹493.70 ₹164.29 -67%

Compare Balchem Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Balchem Corporation (BCPC) overvalued or undervalued?
As of Jul 14, 2026, our model estimates a fair value of $81.93 versus a price of $179.43, about −54% (overvalued).
What is the fair value of BCPC?
Our model-based fair value for Balchem Corporation is $81.93 (as of Jul 14, 2026), built from audited fundamentals. The current price is $179.43.
What is the quality score of BCPC?
Balchem Corporation has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Balchem Corporation (BCPC)?
Balchem Corporation reported trailing-twelve-month revenue of about $1.1B (latest available figure, as of Jul 14, 2026).
What is the net profit margin of BCPC?
The net profit margin of Balchem Corporation is about 15.0%, meaning it keeps roughly 15.0% of revenue as net income. Based on the latest reported figures.
Does Balchem Corporation pay a dividend?
Balchem Corporation currently shows a dividend yield of about 0.61% relative to its recent price (as of Jul 14, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Balchem Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.